Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
G., Piskounova, E
Development Stage and Evidence: advantage goes to Semaglutide
An open-label RCT in n = 44 patients with obesity and subclinical binge-eating found a greater reduction in binge-eating at 12 weeks in liraglutide versus control (diet and exercise) groups [20]
There are newer agents in the pipeline targeting diverse gastric (fundic, antral and pyloric) motor functions, including novel serotonergic 5-HT 4 agonists, dopaminergic D 2/3 antagonists, neurokinin NK 1 antagonists, and ghrelin agonist
US$ 26.49
US$ 24.01
US$ 24.29
US$ 20.46
